S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Thermo Fisher Scientific Inc.

TMO · Healthcare · · USD
613.78 USD
0.00 (-0.75%)
● Updated 2026-09-07 19:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Short-term (Swing)

77
/ 100
Technical 75
Trend & RS 87
Momentum 88
Fundamental (0%) 78
Macro 64
Liquidity 50
ComponentScoreWeight
Technical 75.0 40%
Trend & RS 86.7 20%
Momentum 88.0 20%
Fundamental 77.8 0%
Macro 64.4 15%
Liquidity 50.4 5%

Trade Setup

Entry 613.78
Stop Loss 581.82 (5.2%)
Target 1 (1:1) 645.74 (+5.2%)
Target 2 (2:1) 677.70 (+10.4%)
ATR(14) 15.98 (2.6%)
Risk per Share 31.96
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 48.8 -0.05
Momentum 88.0 +1.52
Quality 42.4 -0.30
Composite 59.7

Quality Scores

Piotroski F-Score 7 /9 — Strong
✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 33.0 22.0 +50% above
P/B Ratio 4.3 4.0 Inline
Dividend Yield 31.0% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
328.77
vs
Market Price
613.78
Upside
-46.4%
Margin of Safety -86.7%
Stage 1 PV (5yr FCF)28,665,955,128
Terminal Value PV92,896,073,219
Total Enterprise Value121,562,028,347

Assumptions

Base FCF5,501,839,884
Growth Rate (5yr)10.5%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
49.88%
Full Kelly
24.94%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 77/100. Estimated win rate 63%, avg win 9.6%, avg loss 3.5%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
57.43
RSI(14)
13.1972
MACD

Relative Strength (RS) IMPROVING

66
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↑ RISING (+25.2% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (7d since high)
Sector Outperformance +22.2% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 57.43 NEUTRAL
Macd 13.1972 BEARISH
Ma Cross 570.73 / 535.44 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.77x NORMAL

Key Levels

LevelPrice
52-Week High647.00
Bollinger Upper642.9
SMA(200)535.44
SMA(50)570.73
SMA(20)611.93
Current Price613.78
Bollinger Lower580.97
52-Week Low435.27
ATR(14)15.98

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 0.89x Normal bar — no special VSA pattern
2026-09-01 Normal 0.86x Normal bar — no special VSA pattern
2026-09-02 Normal 1.01x Normal bar — no special VSA pattern
2026-09-03 Normal 1.13x Normal bar — no special VSA pattern
2026-09-04 Normal 0.77x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 623.26 Above Kijun
Kijun-sen (26) 604.75 Base line
Senkou A 614.00 Leading span A
Senkou B 560.25 Leading span B
Cloud 560.25 – 614.00 Bullish (Green)
Price vs Cloud 613.78 Inside Cloud
Chikou Span 574.30 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 580.97 – 642.9  |  KC: 588.94 – 634.92

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bullish RSI 4
Hidden Bullish RSI 15
Hidden Bullish MACD 15
Regular Bearish RSI 27

Anchored VWAP

VWAP: 528.44 Anchor: 2026-05-18 (52w Low) ABOVE AVWAP +16.1%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/TMO

Valuation

MetricValue
Market Cap226.94B
P/E (TTM)33.00
Forward P/EN/A
P/B4.31
EPS18.60

Financial Health

MetricValue
Revenue Growth10.5%
Profit Margin15.0%
ROE13.5%
Debt/Equity80.58
Current Ratio1.55
Dividend Yield31.0%
Payout RatioN/A
Beta0.85

Trading Data

613.78
Open
613.78
Day High
613.78
Day Low
1.22M
Volume (0.6x avg)

Recent News (8)

Should You Continue to Hold TMO Stock in Your Portfolio?
Zacks · 2026-09-04
‘Corporate America Is Basically Exterminating Your Career.” Clark Howard’s Sounds Alarm For Americans In Their 50s, Who Want To Work Till 65
24/7 Wall St. · 2026-09-04
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
StockStory · 2026-09-04
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
24/7 Wall St. · 2026-09-03
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
Zacks · 2026-09-02
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Zacks · 2026-09-01
Partners Group Private Equity Ltd (LSE:PEY) (Q2 2026) Earnings Call Highlights: Strong ...
GuruFocus.com · 2026-09-01
Thermo Fisher Scientific (TMO) Unveils New Tools For Electron Microscopy And Isotope Analysis
Simply Wall St. · 2026-08-31

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —